Quinten Health is delighted to announce its participation to the first “Life Sciences in the Nordic countries ” mission launched by Bpifrance and operated with Business France. This is a wonderful recognition and an opportunity to dive into the Danish and Swedish healthcare market ecosystem and address its challenges and opportunities!
As part of this mission, Quinten Health will benefit from a business development program to accelerate its development in the Nordic market, the world’s 12th largest economy.
Denmark’s fast-growing pharmaceutical industry accounts for 18% of the country’s exports. In Sweden, it is the 2nd largest export industry. These two countries form one of the most dynamic clusters in Europe: the “Medicon Valley”. Its area of excellence is oncology, one of Quinten Health’s main therapeutic areas, as shown by the recently announced partnership with Unicancer.
During this mission, Quinten Health will be meeting and interacting with decision-makers from the pharmaceutical and medical device sectors, as well as investors, healthcare authorities and research organizations.
A great opportunity, given that the Nordic region is home to some of Europe’s biggest Pharma companies, such as Novo Nordisk and AstraZeneca, and is at the top of international R&D rankings (14% of European unicorns are Swedish and Danish).
